Savara, Inc. (SVRA) Stock Analysis

Q: What is the SVRA stock price target?

Take-profit $9.41 (+85.4% upside). Target $9.41 (+85.6%), stop $4.72 (−7.4%), A.R:R 7.6:1.

Q: What are the risks of investing in SVRA?

Market cap $0.99B below $1B minimum; Market cap $0.99B below $1B minimum.

HoldModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $5.07, but acceptable to hold if already in. Reason: Market cap $0.99B below $1B minimum.

$5.07+85.4% A.UpsideScore 5.1/10#68 of 158 Biotechnology

Stop $4.72Target $9.41(analyst − 13%)A.R:R 7.6:1

Analyst target$10.81+113.3%8 analysts

$9.41our TP

$5.07price

$10.81mean

$16

Hold if already holding. Not a fresh buy at $5.07, but acceptable to hold if already in. Reason: Market cap $0.99B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.99B below $1B minimum. Not in investable universe. Score 5.1/10, moderate confidence.

Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Market cap $0.99B below $1B minimum

Key Metrics

P/E (TTM)—

P/E (Fwd)-14.9

Mkt Cap$994M

EV/EBITDA-8.3

Profit Mgn0.0%

ROE-63.4%

Rev Growth—

Beta0.31

DividendNone

Rating analysts14

Quality Signals

Piotroski F4/9

Options Flow

P/C0.40bullish

IV84%elevated

Max Pain$10+97.2% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.615%0.24

Growth5.015%0.75

Momentum4.910%0.49

Sentiment7.810%0.78

Insider Activity5.010%0.50

Peer Rank2.710%0.27

Technical Setup6.85%0.34

Risk Profile4.85%0.24

Catalyst2.55%0.13

Overall (Σ contributions)5.09

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning (FCF negative)No competitive moatQuality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 13 days

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

1.0

Value Rank

5.0

Growth Rank

5.0

GatesMomentum 4.9<5.5 (soft — BUY_NOW allowed but watch)EARNINGS PROXIMITY 13d<=14d (soft)Momentum 4.9>=4.5A.R:R 7.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

39 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $4.83Resistance $6.24

Price Targets

A.Upside+85.6%

A.R:R7.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Market cap $0.99B below $1B minimum

Earnings

1/4 beats

Next Earnings2026-05-13 (13d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is SVRA stock a buy right now?

Hold if already holding. Not a fresh buy at $5.07, but acceptable to hold if already in. Reason: Market cap $0.99B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.99B below $1B minimum. Not in investable universe. Target $9.41 (+85.6%), stop $4.72 (−7.4%), A.R:R 7.6:1. Score 5.1/10, moderate confidence.

What is the SVRA stock price target?

Take-profit target: $9.41 (+85.4% upside). Target $9.41 (+85.6%), stop $4.72 (−7.4%), A.R:R 7.6:1. Stop-loss: $4.72.

What are the risks of investing in SVRA?

Market cap $0.99B below $1B minimum.

Is SVRA overvalued or undervalued?

Savara, Inc. trades at a P/E of N/A (forward -14.9). TrendMatrix value score: 9.0/10. Verdict: Hold.

What do analysts say about SVRA?

14 analysts cover SVRA with a consensus score of 4.3/5. Average price target: $11.

What does Savara, Inc. do?Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The...

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.